anti-p-gsk3β (ser9)  (Cell Signaling Technology Inc)

Journal: Discover Oncology

Article Title: RRP9 promotes prostate cancer metastasis and epithelial-mesenchymal transition through activation of the AKT/GSK3β/β-Catenin signaling pathway

doi: 10.1007/s12672-025-02833-4

Figure Lengend Snippet: Schematic representation of RRP9-induced promotion of PCa metastasis and EMT via the AKT/GSK3β/β-catenin signaling axis. Upregulation of RRP9 activates AKT through phosphorylation, which subsequently phosphorylates the Ser9 residue of GSK3β. This modification inhibits GSK3β activity, leading to the stabilization and accumulation of β-catenin. The resultant increase in β-catenin levels promotes PCa metastasis and facilitates the EMT process

Article Snippet: The membrane was then washed five times with 1 × TBST solution, each wash lasting 5 min. Next, the membrane was incubated overnight at 4 °C with the following primary antibodies: anti-RRP9 (RS-9, Santa Cruz), anti-N-cadherin (66219–1-lg, Proteintech), anti-Snail (13099–1-AP, Proteintech), anti-Vimentin (80232–1-RR, Proteintech), anti-E-cadherin (60335–1-lg, Proteintech), anti-β-catenin (51067–2-AP, Proteintech), anti-GSK3β (22104–1-AP, Proteintech), anti-p-GSK3β-ser9 (67558–1-lg, Proteintech), anti-AKT (10176–2-AP, Proteintech), anti-p-AKT (66444–1-lg, Proteintech), anti-GAPDH (60004–1-lg, Proteintech), and anti-ACTB (66009–1-lg, Proteintech).

Techniques: Phospho-proteomics, Residue, Modification, Activity Assay